Trial Profile
An International Multicenter Randomized Open-Label Comparative Study of the Efficacy and Safety of BCD-131 (JSC BIOCAD, Russia) and Mircera (F. Hoffmann-La Roche Ltd, Switzerland) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs BCD 131 (Primary) ; Methoxy polyethylene glycol-epoetin beta
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Biocad
- 29 May 2019 Status changed from active, no longer recruiting to completed.
- 13 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 10 May 2018 New trial record